Liver Metastases Treatment Market Report 2026

The liver metastases treatment market size has grown strongly in recent years. It will grow from $1.69 billion in 2025 to $1.82 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to increasing prevalence of colorectal and breast cancer, historical reliance on chemotherapy for metastatic disease, limited surgical options for advanced liver metastases, growing hospital-based oncology care, early adoption of targeted cancer therapies.

The liver metastases treatment market size is expected to see strong growth in the next few years. It will grow to $2.41 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to expansion of immunotherapy pipelines, growing focus on personalized oncology treatment, increasing survival rates of primary cancer patients, rising demand for advanced metastatic cancer care, higher investment in oncology drug development. Major trends in the forecast period include rising incidence of metastatic cancers to the liver, increasing adoption of targeted therapies, growing use of immunotherapy in metastatic liver cancer, expansion of combination treatment approaches, rising focus on improving quality of life outcomes.

The increasing prevalence of liver disease is expected to drive the growth of the liver metastases treatment market in the coming years. Liver disease refers to any condition that impairs the liver’s ability to function properly. Treatments for metastases support overall health by preserving liver function, which is essential for metabolism, detoxification, and other critical bodily processes. Additionally, in certain cases, intensive interventions such as surgical resection, ablation, or targeted therapies are required for long-term remission, particularly when combined with systemic treatments like chemotherapy or immunotherapy. For example, in December 2024, the Office for Health Improvement and Disparities, a UK government department, reported that in 2023, premature deaths from alcoholic liver disease rose by 3.6%, reaching 5,984 compared to 5,776 in 2022. Consequently, the rising incidence of liver disease is driving the liver metastases treatment market.

Major companies operating in the liver metastases treatment market are focusing on developing liver-directed therapies to provide effective and convenient treatment options. Liver-directed therapies involve medicines or interventions that specifically target conditions affecting the liver. These therapies treat liver metastases by concentrating on cancerous cells in the liver, either by destroying them directly or by cutting off their blood supply, using methods such as surgical resection, radiofrequency ablation, transarterial chemoembolization, radioembolization, and stereotactic body radiation therapy. For example, in August 2023, Delcath Systems Incorporated, a US-based interventional oncology company, launched the Hepzato kit, a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or limited extrahepatic disease suitable for resection or radiation. The Hepzato kit is a combination product that delivers melphalan, a chemotherapeutic agent, directly to the liver through Delcath's Hepatic Delivery System (HDS), allowing higher drug exposure in targeted tissues while minimizing systemic toxicity.

In August 2023, TriSalus Life Sciences, a US-based oncology company focused on treatments for patients with liver and pancreatic tumors, completed its merger with MedTech Acquisition Corporation for an undisclosed amount. Through this merger, TriSalus Life Sciences aimed to introduce innovative approaches for treating liver and pancreatic tumors. The company’s proprietary delivery technology enables precise and targeted administration of immunotherapy agents directly to tumor sites, enhancing therapeutic effectiveness while reducing systemic side effects. MedTech Acquisition Corporation is a US-based blank check company.

Major companies operating in the liver metastases treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, Bristol Myers Squibb, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Gilead Sciences Inc., Takeda Pharmaceutical Company, Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Eisai Co. Ltd., Incyte Corporation, Ipsen, Exelixis Inc., Taiho Pharmaceutical Co. Ltd.

North America was the largest region in the liver metastases treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver metastases treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver metastases treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the liver metastases treatment market by increasing costs associated with imported oncology drugs, biologics, and specialty pharmaceutical ingredients. These effects are more pronounced across targeted therapy and immunotherapy segments, particularly in regions such as asia-pacific and europe that depend on global oncology drug supply chains. Hospital and specialty pharmacies face procurement and pricing pressures due to higher import costs. However, tariffs have also encouraged local drug manufacturing, increased availability of generic oncology treatments, and diversification of supply sources, supporting long-term market resilience.

The liver metastases treatment market research report is one of a series of new reports that provides liver metastases treatment market statistics, including liver metastases treatment industry global market size, regional shares, competitors with a liver metastases treatment market share, detailed liver metastases treatment market segments, market trends and opportunities, and any further data you may need to thrive in the liver metastases treatment industry. This liver metastases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liver metastases treatment involves therapeutic approaches designed to manage cancerous growths that have spread to the liver from primary tumors in other parts of the body. This comprehensive treatment approach seeks to improve patient outcomes by reducing or eliminating metastatic lesions, relieving symptoms, and enhancing overall quality of life.

The primary types of liver metastases treatment include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is a cancer treatment that uses drugs to kill cancer cells. It is employed for managing liver metastases originating from various primary cancers, including colorectal cancer and breast cancer, and is distributed through channels such as hospital pharmacies and specialty pharmacies.

The liver metastases treatment market consists of revenues earned by entities by providing services such as surgery, radiotherapy, palliative care, diagnostic imaging, biopsy, ablation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver metastases treatment market also includes sales of therasphere, sir-spheres gamma-90 resin microspheres, Avastin, Nexavar, Keytruda, radiofrequency ablation devices, and cyberknife. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.